Want to see MPLT full AI Analyst Report?
Top Page
MapLight Therapeutics, Inc.
(NASDAQ:MPLT)
Select Model
Select Model
Rating:51Neutral
Price Target:
$12.50
▼(-9.22% Downside)
Action:Reiterated
Date:08/17/26
The score is primarily held back by weak financial performance (no revenue, widening losses, and rising cash burn) and strong bearish technicals (price far below key moving averages and negative MACD). These are partially offset by a strong balance sheet and constructive corporate developments, including positive Phase 2 schizophrenia results and a notable financing that supports program funding through 2028.
Positive Factors
Positive Phase 2 schizophrenia data
ML-007C-MA delivered statistically significant and clinically meaningful schizophrenia benefits, including cognitive improvement and favorable safety. This supports advancement toward pivotal development and could establish a differentiated lead asset in a large unmet-need market.
Negative Factors
Pre-revenue operating model
MapLight has no commercial revenue base to offset research and development costs, leaving its outlook dependent on clinical success and future financing. Until a candidate is approved and launched, operating leverage and earnings visibility remain limited.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive Phase 2 schizophrenia data
ML-007C-MA delivered statistically significant and clinically meaningful schizophrenia benefits, including cognitive improvement and favorable safety. This supports advancement toward pivotal development and could establish a differentiated lead asset in a large unmet-need market.
Read all positive factors
MapLight Therapeutics, Inc. (MPLT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$694.43M
Dividend YieldN/A
Average Volume (3M)1.21M
Price to Earnings (P/E)―
Beta (1Y)0.80
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees133
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding52,848,210
10 Day Avg. Volume624,336
30 Day Avg. Volume1,207,919
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-5.58
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.00Price Target Upside103.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MapLight Therapeutics, Inc. Business Overview & Revenue Model
Company Description
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic ...
MapLight Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -585.00K | -578.00K | -701.00K | -556.00K | -574.00K |
| EBITDA | -232.60M | -160.57M | -76.88M | -55.15M | -29.44M |
| Net Income | -229.83M | -161.15M | -77.58M | -55.71M | -30.02M |
Balance Sheet | |||||
| Total Assets | 368.35M | 479.51M | 136.92M | 91.41M | 39.39M |
| Cash, Cash Equivalents and Short-Term Investments | 304.73M | 305.10M | 108.80M | 79.77M | 27.66M |
| Total Debt | 1.99M | 5.80M | 6.58M | 5.92M | 6.27M |
| Total Liabilities | 20.05M | 21.14M | 21.72M | 20.13M | 18.52M |
| Stockholders Equity | 348.30M | 458.37M | 115.19M | 71.28M | 20.87M |
Cash Flow | |||||
| Free Cash Flow | -175.12M | -138.61M | -79.58M | -52.47M | -27.32M |
| Operating Cash Flow | -174.67M | -138.14M | -78.81M | -52.01M | -26.58M |
| Investing Cash Flow | -250.43M | -323.21M | -80.79M | -462.00K | -746.00K |
| Financing Cash Flow | 463.26M | 469.82M | 118.06M | 104.57M | 33.17M |
MapLight Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | $694.43M | -2.66 | -63.84% | ― | ― | ― | |
49 Neutral | $4.95M | -0.28 | -166.67% | ― | ― | 88.77% | |
48 Neutral | $5.01M | -0.07 | -134.03% | ― | ― | 93.96% | |
45 Neutral | $1.11M | ― | -26.63% | ― | 30.12% | -165.46% | |
44 Neutral | $10.91M | -0.14 | -205.45% | ― | ― | 78.16% |
* General Sector Average
MPLT
MapLight Therapeutics, Inc.
13.77
-4.57
-24.92%
SCNI
Scinai Immunotherapeutics
1.86
-13.14
-87.60%
GRI
GRI Bio
2.88
-43.60
-93.80%
DRMA
Dermata Therapeutics
1.21
-4.05
-77.00%
AZTR
Azitra Inc
0.18
-0.68
-79.14%
MapLight Therapeutics, Inc. Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
MapLight Bolsters Schizophrenia Program With New Financing Round
Positive
Aug 13, 2026
On August 13, 2026, MapLight Therapeutics reported second-quarter 2026 results and business updates, highlighting its focus on central nervous system drug candidates ML-007C-MA and ML-004 while concentrating resources on late-stage clinical progra...
Business Operations and Strategy
MapLight Reports Positive Phase 2 Schizophrenia Trial Results
Positive
Jul 27, 2026
On July 27, 2026, MapLight Therapeutics reported topline Phase 2 data from the ZEPHYR trial of ML-007C-MA in adult inpatients with schizophrenia during acute psychotic exacerbations. The study met its primary endpoint, showing statistically signif...
Executive/Board ChangesShareholder Meetings
MapLight Shareholders Back Board Slate and Auditor
Positive
Jun 24, 2026
On June 23, 2026, MapLight Therapeutics stockholders held their 2026 annual meeting, with approximately 86.56% of the 42.6 million outstanding shares present or represented by proxy. Shareholders elected three directors—Martin Babler, Troy C...
Business Operations and Strategy
MapLight Reports Phase 2 Data for Autism Candidate
Negative
Jun 22, 2026
On June 22, 2026, MapLight Therapeutics reported topline data from its Phase 2 IRIS (ML-004-002) trial evaluating ML-004 in adolescents and adults with autism spectrum disorder. The exploratory, randomized, double-blind, placebo-controlled study d...
Executive/Board Changes
MapLight Therapeutics Names Interim CFO After HR Review
Negative
Jun 18, 2026
On June 18, 2026, MapLight Therapeutics separated Chief Financial Officer Vishwas Setia following a review of a human resources violation, emphasizing that the decision was unrelated to the company’s financial or operating results, internal ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.